Exercise and diet may ease nerve damage and fatigue during chemo
NCT ID NCT03885817
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether a tailored exercise program and nutritional guidance can reduce peripheral neuropathy (nerve damage) and fatigue in people with colorectal cancer receiving chemotherapy. Participants follow a supervised exercise routine and monthly nutrition check-ins during their treatment. The goal is to improve quality of life by managing common side effects of chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an exercise program and nutritional guidance
- What this could lead to
- If it works, this could offer a simple, drug-free way to ease nerve pain and tiredness during chemotherapy.
- What could go wrong
- This is a small, early-stage trial, so results may not apply to everyone. The benefits may be modest or hard to separate from standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kreftklinikken, St Olavs Hospital
Trondheim, Norway
-
Levanger sykehus
Levanger, Norway
-
Sørlandet sykehus, Kristiansand
Kristiansand, Norway
-
Ullevål
Oslo, Norway
-
Ålesund sjukehus
Ålesund, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices